Cargando…
Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension
Arterial wall remodeling underlies increased pulmonary vascular resistance and right heart failure in pulmonary arterial hypertension (PAH). None of the established vasodilator drug therapies for PAH prevents or reverse established arterial wall thickening, stiffening, and hypercontractility. Theref...
Autor principal: | Gerthoffer, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731052/ https://www.ncbi.nlm.nih.gov/pubmed/33287230 http://dx.doi.org/10.3390/ijms21239222 |
Ejemplares similares
-
Insights on the epigenetic mechanisms underlying pulmonary arterial
hypertension
por: Luna, R.C.P., et al.
Publicado: (2018) -
Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
por: Ho, Linh, et al.
Publicado: (2022) -
Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
por: Kim, Jun-Dae, et al.
Publicado: (2015) -
Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
por: Hudson, Jaylen, et al.
Publicado: (2021) -
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis
por: Lee, Michael H, et al.
Publicado: (2019)